Monitoring Report: Respiratory Viruses - November 2025 Data

Samuel Gratzl*, PhD

Karen G Farrar*, PhD

Duy Do, PhD

Nina Masters, MPH, PhD

Brianna M Goodwin Cartwright, MS

* Denotes co-first author
Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Brianna M Goodwin Cartwright
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: briannac@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through November 30, 2025) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2020 and November 30, 2025. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 925,124 hospitalizations of 808,192 unique patients who tested positive for a respiratory virus between October 01, 2020 and November 30, 2025.

Overall, respiratory virus associated hospitalizations increased throughout November 2025. By the last week of the month, respiratory virus associated hospitalizations accounted for 2.5% of all hospitalizations, up from 1.3% at the beginning of November (+91.1%). Influenza-associated hospitalizations increased substantially (+264.7%), COVID-associated hospitalizations rose moderately (+40.2%), and rhinovirus remained the leading cause of virus associated hospitalizations (1.0% of all hospitalizations). HMPV-, parainfluenza-, and RSV-associated hospitalizations remained low and relatively stable across the month. Among children aged 0–4 years, respiratory virus associated hospitalizations increased substantially, reaching 3.9% of all hospitalizations (+73.1%). RSV-associated hospitalizations in the pediatric population continued to double for the third consecutive month and now account for 1.5% of all hospitalizations, however rhinovirus remained the leading cause of respiratory virus-associated hospitalizations in this age group (1.8%). Influenza- and parainfluenza-associated hospitalizations also increased, while COVID- and rhinovirus-associated hospitalizations increased more modestly. Among adults aged 65 years and older, respiratory virus associated hospitalizations increased to 2.8%, up from 1.3% at the beginning of the month (+115.9%). Influenza associated hospitalizations increased substantially (+374.1%)

while COVID associated hospitalizations rose modestly (+37.7%) in this age group. Rhinovirus-associated hospitalizations also increased modestly (+61.0%). RSV-, parainfluenza-, and HMPV-associated hospitalizations remained low and stable.

Discussion: Respiratory virus-associated hospitalizations increased overall during November 2025. In the pediatric population, hospitalization rates rose substantially, with continued increases in RSV- and additional growth in influenza- and parainfluenza-associated hospitalizations. Among older adults, influenza-associated hospitalizations increased notably, with modest increases observed for COVID- and rhinovirus-associated hospitalizations. Together, these trends indicate growing seasonal respiratory virus activity across age groups and underscore the need for continued monitoring as the season progresses, particularly among populations at higher risk for severe outcomes.

Trends in surveillance

Overall population

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 27, 2025	1.3%	0.3%	0.2%	0.0%	0.1%	0.1%	0.8%
November 24, 2025	2.5%	0.5%	0.8%	0.1%	0.2%	0.3%	1.0%
Change (percentage)	+91.1%	+40.2%	+264.7%	+209.2%	+158.0%	+139.5%	+35.8%
Difference (percentage points)	+1.2%	+0.1%	+0.6%	+0.0%	+0.1%	+0.2%	+0.3%

Weekly test positivity rate since October 2020

Change in positivity rate of weekly respiratory virus tests between October 27, 2025 and November 24, 2025

blue background indicate respiratory virus season (Oct - Sep)

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 27, 2025	4.0%	3.2%	3.4%	0.5%	4.1%	2.2%	19.9%
November 24, 2025	6.5%	3.4%	9.3%	1.2%	4.8%	4.3%	17.6%
Change (percentage)	+64.5%	+6.4%	+172.6%	+134.4%	+15.4%	+94.9%	-11.3%
Difference (percentage points)	+2.6%	+0.2%	+5.9%	+0.7%	+0.6%	+2.1%	-2.3%

In the last week of November, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations, an increase from 1.3% at the beginning of the month (+91.1%). Influenza-associated hospitalizations increased from 0.2% of to 0.8% of all hospitalizations (+264.7%), COIVD-associated hospitalizations increased from 0.3% to 0.5% of all hospitalizations (+40.2%), RSV increased slightly from 0.1% to 0.3% of all hospitalizations, and rhinovirus-associated hospitalizations increased slightly from 0.8% to 1.0% of all hospitalizations. HMPV-, parainfluenza-associated hospitalizations all remained relatively low and stable across the month.

Influenza, HMPV, and RSV test positivity increased notably (+172.6%, +134.4%, and +94.9%, respectively), while parainfluenza and COVID test positivity increased slightly (+15.4% and +6.4%, respectively). Rhinovirus continued to show the highest positivity levels (17.6%) but decreased this month. These data suggest that although respiratory virus associated hospitalizations remained low overall in November, hospitalizations associated with respiratory viruses are beginning to increase. Increases were observed across most respiratory viruses in both hospitalizations and test positivity. Rhinovirus continued to account for the largest share of virus-associated hospitalizations and maintained the highest positivity levels, while notable increases in influenza-associated hospitalizations were also observed.

Infants and children (age 0-4)

Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Change in rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions between October 27, 2025 and November 24, 2025 for infants and children under five

Overall +73.1%   COVID +33.6%   influenza +62.3%   HMPV +337.3%   parainfluenza +155.1%   RSV +146.0%   rhinovirus +28.1%

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 27, 2025	2.2%	0.4%	0.5%	0.0%	0.2%	0.6%	1.4%
November 24, 2025	3.9%	0.6%	0.8%	0.1%	0.5%	1.5%	1.8%
Change (percentage)	+73.1%	+33.6%	+62.3%	+337.3%	+155.1%	+146.0%	+28.1%
Difference (percentage points)	+1.6%	+0.1%	+0.3%	+0.1%	+0.3%	+0.9%	+0.4%

Weekly test positivity rate since October 2020 for infants and children under five

Change in weekly test positivity rate between October 27, 2025 and November 24, 2025 for infants and children under five

Overall +35.9%   COVID +16.4%   influenza +157.1%   HMPV +202.8%   parainfluenza -8.1%   RSV +71.5%   rhinovirus -18.5%

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 27, 2025	8.2%	3.0%	4.1%	0.9%	12.7%	8.2%	46.6%
November 24, 2025	11.2%	3.5%	10.5%	2.8%	11.7%	14.1%	38.0%
Change (percentage)	+35.9%	+16.4%	+157.1%	+202.8%	-8.1%	+71.5%	-18.5%
Difference (percentage points)	+3.0%	+0.5%	+6.4%	+1.8%	-1.0%	+5.9%	-8.6%

In the population aged 0–4 years, respiratory virus–associated hospitalizations increased substantially throughout November and are now at a rate of 3.9% of all hospitalizations in this age group (+73.1%). For the third month in a row, the rate of RSV-associated hospitalizations more than doubled, now accounting for 1.5% of all

hospitalizations within this age group. Parainfluenza- and influenza- associated hospitalizations also increased substantially across this month (155.1% and +62.3%, respectively), while COVID- and rhinovirus increased modestly (+33.6% and 28.1%, respectively). Rhinovirus (1.8%) continues to account for the largest share of respiratory virus associated hospitalizations in this age group, although RSV (1.5%) is now a close second.

In this pediatric population, HMPV, influenza, RSV, and test positivity increased substantially (+202.8%, +157.1%, +71.5%, respectively). COVID test positivity increased slightly (+16.4 percent), while rhinovirus and parainfluenza test positivity declined. Rhinovirus remained the virus with the highest test positivity rate (38.0 %) despite this decrease. These data demonstrate that respiratory virus-associated hospitalizations are increasing among children aged 0 to 4 years, marked by increasing RSV- and influenza-associated hospitalizations.

Older adults (age 65 and over)

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 27, 2025	1.3%	0.4%	0.2%	0.0%	0.1%	0.1%	0.6%
November 24, 2025	2.8%	0.6%	0.9%	0.1%	0.2%	0.2%	0.9%
Change (percentage)	+115.9%	+37.7%	+374.1%	+146.4%	+264.8%	+164.1%	+61.0%
Difference (percentage points)	+1.5%	+0.2%	+0.7%	+0.0%	+0.2%	+0.1%	+0.4%

Weekly test positivity rate since October 2020 for adults 65 years or older

Change in weekly test positivity rate between October 27, 2025 and November 24, 2025 for adults 65 years or older

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 27, 2025	2.3%	3.5%	1.5%	0.4%	1.0%	0.6%	8.3%
November 24, 2025	3.4%	3.5%	4.0%	0.7%	2.2%	1.3%	9.4%
Change (percentage)	+50.2%	-1.2%	+164.9%	+96.3%	+116.0%	+106.6%	+13.1%
Difference (percentage points)	+1.1%	-0.0%	+2.5%	+0.3%	+1.2%	+0.7%	+1.1%

Among adults aged 65 years and older, respiratory virus–associated hospitalizations accounted for 2.8% of all hospitalizations in the last week of November 2025, an increase from 1.3% at the beginning of the month (+115.9%). Influenza-associated hospitalizations increased substantially (+374.1 percent) and now represent 0.9 % of all hospitalizations in this age group. COVID-associated hospitalizations increased modestly, from 0.4% to 0.6% (+37.7%). Rhinovirus associated hospitalizations also increased modestly, from 0.6% to 0.9% (+61.0%). RSV, parainfluenza, and HMPV associated hospitalizations remained low and relatively stable across the month.

In this older adult population, influenza test positivity increased sharply (+164.9 percent). Parainfluenza, RSV, and HMPV positivity also increased across the month (+116.0%, +106.6%, and +96.3%, respectively). COVID test positivity remained stable, while rhinovirus positivity increased slightly (+13.1 percent) and continued to be the highest among all respiratory viruses.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults

(Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2020 and November 30, 2025 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record

(EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on December 10, 2025 and included de-identified patient care data primarily located across ten states: California, Florida, New York, Texas, Virginia, Illinois, Washington, Ohio, Michigan, and Arizona.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 925,124 hospitalizations of 808,192 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	189,180 (100.00%)	203,054 (100.00%)	147,332 (100.00%)	140,678 (100.00%)	118,196 (100.00%)	9,752 (100.00%)	808,192 (100.00%)
Age Group							
< 6 months	1,683 (0.89%)	3,017 (1.49%)	3,998 (2.71%)	3,188 (2.27%)	2,487 (2.10%)	301 (3.09%)	14,674 (1.82%)
6 - <12 months	746 (0.39%)	1,446 (0.71%)	1,987 (1.35%)	1,733 (1.23%)	1,516 (1.28%)	157 (1.61%)	7,585 (0.94%)
1 - <2 years	1,238 (0.65%)	2,069 (1.02%)	2,716 (1.84%)	2,263 (1.61%)	2,366 (2.00%)	321 (3.29%)	10,973 (1.36%)
2 - 4 years	1,341 (0.71%)	3,077 (1.52%)	3,939 (2.67%)	2,875 (2.04%)	3,032 (2.57%)	426 (4.37%)	14,690 (1.82%)
5 - 17 years	2,317 (1.22%)	3,856 (1.90%)	4,515 (3.06%)	4,008 (2.85%)	4,088 (3.46%)	587 (6.02%)	19,371 (2.40%)
18 - 49 years	43,704 (23.10%)	43,258 (21.30%)	21,168 (14.37%)	19,689 (14.00%)	17,332 (14.66%)	1,584 (16.24%)	146,735 (18.16%)
50 - 64 years	48,384 (25.58%)	42,523 (20.94%)	23,970 (16.27%)	23,370 (16.61%)	20,263 (17.14%)	1,597 (16.38%)	160,107 (19.81%)
65 - 74 years	38,862 (20.54%)	40,631 (20.01%)	28,811 (19.56%)	28,394 (20.18%)	23,754 (20.10%)	1,731 (17.75%)	162,183 (20.07%)
75 - 84 years	32,504 (17.18%)	38,679 (19.05%)	32,987 (22.39%)	32,898 (23.39%)	26,467 (22.39%)	1,864 (19.11%)	165,399 (20.47%)
85+ years	18,401 (9.73%)	24,498 (12.06%)	23,241 (15.77%)	22,260 (15.82%)	16,891 (14.29%)	1,184 (12.14%)	106,475 (13.17%)
Sex							
Female	93,207 (49.27%)	104,601 (51.51%)	77,446 (52.57%)	73,840 (52.49%)	62,566 (52.93%)	5,025 (51.53%)	416,685 (51.56%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Male	95,362 (50.41%)	97,777 (48.15%)	69,341 (47.06%)	66,272 (47.11%)	55,241 (46.74%)	4,640 (47.58%)	388,633 (48.09%)
Other	3 (0.00%)	1 (0.00%)	4 (0.00%)	1 (0.00%)	1 (0.00%)	0	10 (0.00%)
Unknown	608 (0.32%)	675 (0.33%)	541 (0.37%)	565 (0.40%)	388 (0.33%)	87 (0.89%)	2,864 (0.35%)
Race							
White	120,434 (63.66%)	135,652 (66.81%)	97,364 (66.08%)	91,543 (65.07%)	77,231 (65.34%)	5,991 (61.43%)	528,215 (65.36%)
Black or African American	28,548 (15.09%)	28,950 (14.26%)	20,370 (13.83%)	20,859 (14.83%)	17,071 (14.44%)	1,593 (16.34%)	117,391 (14.53%)
Asian	4,504 (2.38%)	4,617 (2.27%)	4,430 (3.01%)	3,845 (2.73%)	3,325 (2.81%)	282 (2.89%)	21,003 (2.60%)
Native Hawaiian or Other Pacific Islander	957 (0.51%)	1,003 (0.49%)	743 (0.50%)	744 (0.53%)	705 (0.60%)	55 (0.56%)	4,207 (0.52%)
American Indian or Alaska Native	1,128 (0.60%)	1,251 (0.62%)	922 (0.63%)	774 (0.55%)	685 (0.58%)	61 (0.63%)	4,821 (0.60%)
Other Race	13,232 (6.99%)	11,275 (5.55%)	9,290 (6.31%)	8,838 (6.28%)	8,466 (7.16%)	877 (8.99%)	51,978 (6.43%)
Unknown	20,377 (10.77%)	20,306 (10.00%)	14,213 (9.65%)	14,075 (10.01%)	10,713 (9.06%)	893 (9.16%)	80,577 (9.97%)
Ethnicity							
Hispanic or Latino	22,274 (11.77%)	18,209 (8.97%)	14,502 (9.84%)	15,035 (10.69%)	14,776 (12.50%)	1,510 (15.48%)	86,306 (10.68%)
Not Hispanic or Latino	146,101 (77.23%)	165,607 (81.56%)	119,685 (81.23%)	113,734 (80.85%)	95,092 (80.45%)	7,714 (79.10%)	647,933 (80.17%)
Unknown	20,805 (11.00%)	19,238 (9.47%)	13,145 (8.92%)	11,909 (8.47%)	8,328 (7.05%)	528 (5.41%)	73,953 (9.15%)
Virus							
COVID	171,970 (90.90%)	171,468 (84.44%)	82,114 (55.73%)	70,471 (50.09%)	35,558 (30.08%)	2,706 (27.75%)	534,287 (66.11%)
HMPV	86 (0.05%)	2,712 (1.34%)	4,625 (3.14%)	3,841 (2.73%)	4,940 (4.18%)	191 (1.96%)	16,395 (2.03%)
RSV	2,115 (1.12%)	4,620 (2.28%)	8,929 (6.06%)	10,806 (7.68%)	11,378 (9.63%)	660 (6.77%)	38,508 (4.76%)
influenza	7,248 (3.83%)	13,269 (6.53%)	33,050 (22.43%)	35,276 (25.08%)	41,069 (34.75%)	1,170 (12.00%)	131,082 (16.22%)
parainfluenza	1,416 (0.75%)	2,252 (1.11%)	4,307 (2.92%)	4,463 (3.17%)	4,938 (4.18%)	655 (6.72%)	18,031 (2.23%)
rhinovirus	6,345 (3.35%)	8,733 (4.30%)	14,307 (9.71%)	15,821 (11.25%)	20,313 (17.19%)	4,370 (44.81%)	69,889 (8.65%)
Comorbidity							
Asthma	16,915 (8.94%)	21,130 (10.41%)	18,572 (12.61%)	19,325 (13.74%)	18,463 (15.62%)	1,633 (16.75%)	96,038 (11.88%)
Chronic Lung Disease	11,767 (6.22%)	13,599 (6.70%)	11,198 (7.60%)	11,348 (8.07%)	11,142 (9.43%)	882 (9.04%)	59,936 (7.42%)
Chronic Obstructive Pulmonary Disease	21,831 (11.54%)	31,077 (15.30%)	26,757 (18.16%)	27,743 (19.72%)	24,476 (20.71%)	1,782 (18.27%)	133,666 (16.54%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020

Test positivity rate over time

We included 70,382,522 lab results with known results of which 6,471,405 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2020

COVID-19

Our COVID study population consists of 556,623 hospitalizations of 534,287 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	171,970 (100.00%)	171,468 (100.00%)	82,114 (100.00%)	70,471 (100.00%)	35,558 (100.00%)	2,706 (100.00%)	534,287 (100.00%)
Age Group							
< 6 months	319 (0.19%)	820 (0.48%)	394 (0.48%)	417 (0.59%)	398 (1.12%)	36 (1.33%)	2,384 (0.45%)
6 - <12 months	55 (0.03%)	257 (0.15%)	184 (0.22%)	209 (0.30%)	236 (0.66%)	19 (0.70%)	960 (0.18%)
1 - <2 years	89 (0.05%)	235 (0.14%)	129 (0.16%)	259 (0.37%)	458 (1.29%)	54 (2.00%)	1,224 (0.23%)
2 - 4 years	129 (0.08%)	343 (0.20%)	124 (0.15%)	259 (0.37%)	616 (1.73%)	83 (3.07%)	1,554 (0.29%)
5 - 17 years	1,083 (0.63%)	1,568 (0.91%)	530 (0.65%)	587 (0.83%)	974 (2.74%)	130 (4.80%)	4,872 (0.91%)
18 - 49 years	40,586 (23.60%)	38,427 (22.41%)	11,107 (13.53%)	7,935 (11.26%)	4,124 (11.60%)	318 (11.75%)	102,497 (19.18%)
50 - 64 years	45,362 (26.38%)	37,733 (22.01%)	12,931 (15.75%)	10,484 (14.88%)	4,829 (13.58%)	356 (13.16%)	111,695 (20.91%)
65 - 74 years	36,476 (21.21%)	35,894 (20.93%)	17,571 (21.40%)	15,263 (21.66%)	7,118 (20.02%)	538 (19.88%)	112,860 (21.12%)
75 - 84 years	30,594 (17.79%)	34,445 (20.09%)	22,484 (27.38%)	20,392 (28.94%)	9,919 (27.90%)	686 (25.35%)	118,520 (22.18%)
85+ years	17,277 (10.05%)	21,746 (12.68%)	16,660 (20.29%)	14,666 (20.81%)	6,886 (19.37%)	486 (17.96%)	77,721 (14.55%)
Sex							
Female	84,539 (49.16%)	88,124 (51.39%)	42,669 (51.96%)	36,009 (51.10%)	18,245 (51.31%)	1,353 (50.00%)	270,939 (50.71%)
Male	86,864 (50.51%)	82,752 (48.26%)	39,112 (47.63%)	34,130 (48.43%)	17,155 (48.25%)	1,320 (48.78%)	261,333 (48.91%)
Other	3 (0.00%)	1 (0.00%)	2 (0.00%)	1 (0.00%)	0	0	7 (0.00%)
Unknown	564 (0.33%)	591 (0.34%)	331 (0.40%)	331 (0.47%)	158 (0.44%)	33 (1.22%)	2,008 (0.38%)
Race							
White	110,555 (64.29%)	116,275 (67.81%)	57,754 (70.33%)	48,820 (69.28%)	23,646 (66.50%)	1,706 (63.05%)	358,756 (67.15%)
Black or African American	25,591 (14.88%)	24,296 (14.17%)	10,103 (12.30%)	8,849 (12.56%)	4,733 (13.31%)	348 (12.86%)	73,920 (13.84%)
Asian	3,895 (2.26%)	3,413 (1.99%)	1,993 (2.43%)	1,900 (2.70%)	1,210 (3.40%)	132 (4.88%)	12,543 (2.35%)
Native Hawaiian or Other Pacific Islander	864 (0.50%)	750 (0.44%)	302 (0.37%)	283 (0.40%)	142 (0.40%)	7 (0.26%)	2,348 (0.44%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
American Indian or Alaska Native	1,005 (0.58%)	1,001 (0.58%)	418 (0.51%)	361 (0.51%)	190 (0.53%)	17 (0.63%)	2,992 (0.56%)
Other Race	11,241 (6.54%)	8,226 (4.80%)	3,628 (4.42%)	3,282 (4.66%)	2,282 (6.42%)	233 (8.61%)	28,892 (5.41%)
Unknown	18,819 (10.94%)	17,507 (10.21%)	7,916 (9.64%)	6,976 (9.90%)	3,355 (9.44%)	263 (9.72%)	54,836 (10.26%)
Ethnicity							
Hispanic or Latino	20,138 (11.71%)	14,069 (8.21%)	5,919 (7.21%)	5,720 (8.12%)	3,340 (9.39%)	264 (9.76%)	49,450 (9.26%)
Not Hispanic or Latino	132,886 (77.27%)	140,937 (82.19%)	68,707 (83.67%)	58,643 (83.22%)	29,521 (83.02%)	2,247 (83.04%)	432,941 (81.03%)
Unknown	18,946 (11.02%)	16,462 (9.60%)	7,488 (9.12%)	6,108 (8.67%)	2,697 (7.58%)	195 (7.21%)	51,896 (9.71%)
Comorbidity							
Asthma	14,429 (8.39%)	16,389 (9.56%)	8,516 (10.37%)	8,138 (11.55%)	4,643 (13.06%)	370 (13.67%)	52,485 (9.82%)
Chronic Lung Disease	10,567 (6.14%)	11,172 (6.52%)	6,108 (7.44%)	5,645 (8.01%)	2,947 (8.29%)	243 (8.98%)	36,682 (6.87%)
Chronic Obstructive Pulmonary Disease	19,282 (11.21%)	25,742 (15.01%)	14,978 (18.24%)	14,236 (20.20%)	6,901 (19.41%)	493 (18.22%)	81,632 (15.28%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2020

Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 35,081,335 COVID lab results with known results of which 3,740,414 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2020

Figure 7: Weekly COVID test positivity rate by season

Influenza

Our influenza study population consists of 163,861 hospitalizations of 131,082 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	7,248 (100.00%)	13,269 (100.00%)	33,050 (100.00%)	35,276 (100.00%)	41,069 (100.00%)	1,170 (100.00%)	131,082 (100.00%)
Age Group							
< 6 months	292 (4.03%)	455 (3.43%)	779 (2.36%)	523 (1.48%)	115 (0.28%)	9 (0.77%)	2,173 (1.66%)
6 - <12 months	164 (2.26%)	309 (2.33%)	465 (1.41%)	320 (0.91%)	99 (0.24%)	5 (0.43%)	1,362 (1.04%)
1 - <2 years	318 (4.39%)	521 (3.93%)	710 (2.15%)	428 (1.21%)	159 (0.39%)	10 (0.85%)	2,146 (1.64%)
2 - 4 years	474 (6.54%)	989 (7.45%)	1,308 (3.96%)	722 (2.05%)	274 (0.67%)	18 (1.54%)	3,785 (2.89%)
5 - 17 years	565 (7.80%)	1,007 (7.59%)	1,968 (5.95%)	1,425 (4.04%)	844 (2.06%)	69 (5.90%)	5,878 (4.48%)
18 - 49 years	1,323 (18.25%)	2,403 (18.11%)	5,811 (17.58%)	6,839 (19.39%)	6,908 (16.82%)	214 (18.29%)	23,498 (17.93%)
50 - 64 years	1,440 (19.87%)	2,055 (15.49%)	6,192 (18.74%)	7,334 (20.79%)	8,657 (21.08%)	187 (15.98%)	25,865 (19.73%)
65 - 74 years	1,145 (15.80%)	2,118 (15.96%)	6,244 (18.89%)	7,226 (20.48%)	9,380 (22.84%)	233 (19.91%)	26,346 (20.10%)
75 - 84 years	957 (13.20%)	2,020 (15.22%)	5,908 (17.88%)	6,679 (18.93%)	9,254 (22.53%)	265 (22.65%)	25,083 (19.14%)
85+ years	570 (7.86%)	1,392 (10.49%)	3,665 (11.09%)	3,780 (10.72%)	5,379 (13.10%)	160 (13.68%)	14,946 (11.40%)
Sex							
Female	3,474 (47.93%)	7,015 (52.87%)	17,818 (53.91%)	19,290 (54.68%)	22,428 (54.61%)	625 (53.42%)	70,650 (53.90%)
Male	3,748 (51.71%)	6,211 (46.81%)	15,112 (45.72%)	15,859 (44.96%)	18,540 (45.14%)	538 (45.98%)	60,008 (45.78%)
Other	0	0	2 (0.01%)	0	0	0	2 (0.00%)
Unknown	26 (0.36%)	43 (0.32%)	118 (0.36%)	127 (0.36%)	101 (0.25%)	7 (0.60%)	422 (0.32%)
Race							
White	3,359 (46.34%)	6,880 (51.85%)	18,331 (55.46%)	20,088 (56.95%)	26,988 (65.71%)	654 (55.90%)	76,300 (58.21%)
Black or African American	1,411 (19.47%)	2,236 (16.85%)	6,000 (18.15%)	7,207 (20.43%)	6,238 (15.19%)	242 (20.68%)	23,334 (17.80%)
Asian	414 (5.71%)	763 (5.75%)	1,538 (4.65%)	1,142 (3.24%)	1,098 (2.67%)	46 (3.93%)	5,001 (3.82%)
Native Hawaiian or Other Pacific Islander	7 (0.10%)	63 (0.47%)	152 (0.46%)	190 (0.54%)	212 (0.52%)	10 (0.85%)	634 (0.48%)
American Indian or Alaska Native	46 (0.63%)	83 (0.63%)	232 (0.70%)	193 (0.55%)	253 (0.62%)	7 (0.60%)	814 (0.62%)
Other Race	1,302 (17.96%)	1,904 (14.35%)	3,377 (10.22%)	2,885 (8.18%)	2,770 (6.74%)	108 (9.23%)	12,346 (9.42%)
Unknown	709 (9.78%)	1,340 (10.10%)	3,420 (10.35%)	3,571 (10.12%)	3,510 (8.55%)	103 (8.80%)	12,653 (9.65%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Ethnicity							
Hispanic or Latino	904 (12.47%)	1,669 (12.58%)	3,761 (11.38%)	3,867 (10.96%)	4,855 (11.82%)	182 (15.56%)	15,238 (11.62%)
Not Hispanic or Latino	5,245 (72.36%)	10,138 (76.40%)	25,970 (78.58%)	28,116 (79.70%)	33,355 (81.22%)	934 (79.83%)	103,758 (79.16%)
Unknown	1,099 (15.16%)	1,462 (11.02%)	3,319 (10.04%)	3,293 (9.33%)	2,859 (6.96%)	54 (4.62%)	12,086 (9.22%)
Comorbidity							
Asthma	718 (9.91%)	1,800 (13.57%)	4,766 (14.42%)	5,231 (14.83%)	6,422 (15.64%)	191 (16.32%)	19,128 (14.59%)
Chronic Lung Disease	224 (3.09%)	735 (5.54%)	2,256 (6.83%)	2,641 (7.49%)	4,008 (9.76%)	94 (8.03%)	9,958 (7.60%)
Chronic Obstructive Pulmonary Disease	697 (9.62%)	1,950 (14.70%)	5,758 (17.42%)	6,618 (18.76%)	9,114 (22.19%)	171 (14.62%)	24,308 (18.54%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 19,581,644 influenza lab results with known results of which 1,784,512 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2020

Figure 11: Weekly influenza test positivity rate by season

Human metapneumovirus (HMPV)

Our HMPV study population consists of 22,266 hospitalizations of 16,395 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	86 (100.00%)	2,712 (100.00%)	4,625 (100.00%)	3,841 (100.00%)	4,940 (100.00%)	191 (100.00%)	16,395 (100.00%)
Age Group							
< 6 months	1 (1.16%)	78 (2.88%)	178 (3.85%)	92 (2.40%)	108 (2.19%)	3 (1.57%)	460 (2.81%)
6 - <12 months	3 (3.49%)	106 (3.91%)	150 (3.24%)	116 (3.02%)	111 (2.25%)	5 (2.62%)	491 (2.99%)
1 - <2 years	10 (11.63%)	162 (5.97%)	193 (4.17%)	108 (2.81%)	137 (2.77%)	5 (2.62%)	615 (3.75%)
2 - 4 years	11 (12.79%)	242 (8.92%)	321 (6.94%)	169 (4.40%)	177 (3.58%)	8 (4.19%)	928 (5.66%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
5 - 17 years	2 (2.33%)	121 (4.46%)	182 (3.94%)	124 (3.23%)	136 (2.75%)	8 (4.19%)	573 (3.49%)
18 - 49 years	13 (15.12%)	322 (11.87%)	497 (10.75%)	472 (12.29%)	610 (12.35%)	29 (15.18%)	1,943 (11.85%)
50 - 64 years	20 (23.26%)	492 (18.14%)	783 (16.93%)	702 (18.28%)	836 (16.92%)	36 (18.85%)	2,869 (17.50%)
65 - 74 years	8 (9.30%)	474 (17.48%)	868 (18.77%)	727 (18.93%)	977 (19.78%)	50 (26.18%)	3,104 (18.93%)
75 - 84 years	12 (13.95%)	454 (16.74%)	894 (19.33%)	827 (21.53%)	1,111 (22.49%)	28 (14.66%)	3,326 (20.29%)
85+ years	6 (6.98%)	261 (9.62%)	559 (12.09%)	504 (13.12%)	737 (14.92%)	19 (9.95%)	2,086 (12.72%)
Sex							
Female	40 (46.51%)	1,539 (56.75%)	2,700 (58.38%)	2,324 (60.51%)	2,851 (57.71%)	106 (55.50%)	9,560 (58.31%)
Male	45 (52.33%)	1,168 (43.07%)	1,916 (41.43%)	1,503 (39.13%)	2,073 (41.96%)	82 (42.93%)	6,787 (41.40%)
Unknown	1 (1.16%)	5 (0.18%)	9 (0.19%)	14 (0.36%)	16 (0.32%)	3 (1.57%)	48 (0.29%)
Race							
White	59 (68.60%)	1,975 (72.82%)	3,278 (70.88%)	2,546 (66.28%)	3,361 (68.04%)	120 (62.83%)	11,339 (69.16%)
Black or African American	7 (8.14%)	304 (11.21%)	470 (10.16%)	465 (12.11%)	622 (12.59%)	26 (13.61%)	1,894 (11.55%)
Asian	0	54 (1.99%)	127 (2.75%)	86 (2.24%)	137 (2.77%)	5 (2.62%)	409 (2.49%)
Native Hawaiian or Other Pacific Islander	0	18 (0.66%)	16 (0.35%)	17 (0.44%)	20 (0.40%)	2 (1.05%)	73 (0.45%)
American Indian or Alaska Native	1 (1.16%)	18 (0.66%)	42 (0.91%)	24 (0.62%)	20 (0.40%)	1 (0.52%)	106 (0.65%)
Other Race	10 (11.63%)	157 (5.79%)	324 (7.01%)	313 (8.15%)	346 (7.00%)	17 (8.90%)	1,167 (7.12%)
Unknown	9 (10.47%)	186 (6.86%)	368 (7.96%)	390 (10.15%)	434 (8.79%)	20 (10.47%)	1,407 (8.58%)
Ethnicity							
Hispanic or Latino	20 (23.26%)	344 (12.68%)	664 (14.36%)	618 (16.09%)	725 (14.68%)	33 (17.28%)	2,404 (14.66%)
Not Hispanic or Latino	60 (69.77%)	2,182 (80.46%)	3,674 (79.44%)	2,955 (76.93%)	3,874 (78.42%)	150 (78.53%)	12,895 (78.65%)
Unknown	6 (6.98%)	186 (6.86%)	287 (6.21%)	268 (6.98%)	341 (6.90%)	8 (4.19%)	1,096 (6.68%)
Comorbidity							
Asthma	11 (12.79%)	412 (15.19%)	758 (16.39%)	675 (17.57%)	849 (17.19%)	31 (16.23%)	2,736 (16.69%)
Chronic Lung Disease	11 (12.79%)	306 (11.28%)	470 (10.16%)	370 (9.63%)	553 (11.19%)	24 (12.57%)	1,734 (10.58%)
Chronic Obstructive Pulmonary Disease	15 (17.44%)	554 (20.43%)	954 (20.63%)	782 (20.36%)	1,074 (21.74%)	22 (11.52%)	3,401 (20.74%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2020

Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 2,406,476 HMPV lab results with known results of which 61,759 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2020

Figure 15: Weekly HMPV test positivity rate by season

Weekly HMPV test positivity rate by season

Parainfluenza virus

Our parainfluenza study population consists of 25,028 hospitalizations of 18,031 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	1,416 (100.00%)	2,252 (100.00%)	4,307 (100.00%)	4,463 (100.00%)	4,938 (100.00%)	655 (100.00%)	18,031 (100.00%)
Age Group							
< 6 months	84 (5.93%)	107 (4.75%)	207 (4.81%)	159 (3.56%)	142 (2.88%)	26 (3.97%)	725 (4.02%)
6 - <12 months	67 (4.73%)	77 (3.42%)	126 (2.93%)	101 (2.26%)	89 (1.80%)	22 (3.36%)	482 (2.67%)
1 - <2 years	100 (7.06%)	97 (4.31%)	184 (4.27%)	149 (3.34%)	142 (2.88%)	40 (6.11%)	712 (3.95%)
2 - 4 years	85 (6.00%)	135 (5.99%)	226 (5.25%)	166 (3.72%)	151 (3.06%)	37 (5.65%)	800 (4.44%)
5 - 17 years	66 (4.66%)	105 (4.66%)	190 (4.41%)	128 (2.87%)	157 (3.18%)	43 (6.56%)	689 (3.82%)
18 - 49 years	211 (14.90%)	295 (13.10%)	519 (12.05%)	540 (12.10%)	620 (12.56%)	89 (13.59%)	2,274 (12.61%)
50 - 64 years	291 (20.55%)	454 (20.16%)	800 (18.57%)	818 (18.33%)	858 (17.38%)	105 (16.03%)	3,326 (18.45%)
65 - 74 years	227 (16.03%)	422 (18.74%)	784 (18.20%)	937 (20.99%)	1,036 (20.98%)	114 (17.40%)	3,520 (19.52%)
75 - 84 years	185 (13.06%)	329 (14.61%)	765 (17.76%)	930 (20.84%)	1,062 (21.51%)	110 (16.79%)	3,381 (18.75%)
85+ years	100 (7.06%)	231 (10.26%)	506 (11.75%)	535 (11.99%)	681 (13.79%)	69 (10.53%)	2,122 (11.77%)
Sex							
Female	761 (53.74%)	1,259 (55.91%)	2,336 (54.24%)	2,434 (54.54%)	2,710 (54.88%)	345 (52.67%)	9,845 (54.60%)
Male	653 (46.12%)	991 (44.01%)	1,957 (45.44%)	2,019 (45.24%)	2,212 (44.80%)	307 (46.87%)	8,139 (45.14%)
Unknown	2 (0.14%)	2 (0.09%)	14 (0.33%)	10 (0.22%)	16 (0.32%)	3 (0.46%)	47 (0.26%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Race							
White	974 (68.79%)	1,586 (70.43%)	2,968 (68.91%)	2,945 (65.99%)	3,301 (66.85%)	443 (67.63%)	12,217 (67.76%)
Black or African American	188 (13.28%)	272 (12.08%)	518 (12.03%)	565 (12.66%)	618 (12.52%)	82 (12.52%)	2,243 (12.44%)
Asian	16 (1.13%)	49 (2.18%)	108 (2.51%)	104 (2.33%)	124 (2.51%)	10 (1.53%)	411 (2.28%)
Native Hawaiian or Other Pacific Islander	6 (0.42%)	10 (0.44%)	22 (0.51%)	37 (0.83%)	20 (0.41%)	4 (0.61%)	99 (0.55%)
American Indian or Alaska Native	15 (1.06%)	20 (0.89%)	37 (0.86%)	28 (0.63%)	29 (0.59%)	5 (0.76%)	134 (0.74%)
Other Race	91 (6.43%)	119 (5.28%)	312 (7.24%)	317 (7.10%)	371 (7.51%)	60 (9.16%)	1,270 (7.04%)
Unknown	126 (8.90%)	196 (8.70%)	342 (7.94%)	467 (10.46%)	475 (9.62%)	51 (7.79%)	1,657 (9.19%)
Ethnicity							
Hispanic or Latino	144 (10.17%)	263 (11.68%)	584 (13.56%)	661 (14.81%)	676 (13.69%)	112 (17.10%)	2,440 (13.53%)
Not Hispanic or Latino	1,159 (81.85%)	1,814 (80.55%)	3,383 (78.55%)	3,483 (78.04%)	3,946 (79.91%)	507 (77.40%)	14,292 (79.26%)
Unknown	113 (7.98%)	175 (7.77%)	340 (7.89%)	319 (7.15%)	316 (6.40%)	36 (5.50%)	1,299 (7.20%)
Comorbidity							
Asthma	252 (17.80%)	399 (17.72%)	708 (16.44%)	735 (16.47%)	848 (17.17%)	99 (15.11%)	3,041 (16.87%)
Chronic Lung Disease	155 (10.95%)	284 (12.61%)	478 (11.10%)	493 (11.05%)	574 (11.62%)	64 (9.77%)	2,048 (11.36%)
Chronic Obstructive Pulmonary Disease	326 (23.02%)	573 (25.44%)	1,017 (23.61%)	1,138 (25.50%)	1,229 (24.89%)	120 (18.32%)	4,403 (24.42%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 2,501,177 parainfluenza lab results with known results of which 99,012 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2020

Figure 19: Weekly parainfluenza test positivity rate by season

Respiratory syncytial virus (RSV)

Our RSV study population consists of 54,369 hospitalizations of 38,508 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	2,115 (100.00%)	4,620 (100.00%)	8,929 (100.00%)	10,806 (100.00%)	11,378 (100.00%)	660 (100.00%)	38,508 (100.00%)
Age Group							
< 6 months	551 (26.05%)	845 (18.29%)	1,588 (17.78%)	1,172 (10.85%)	873 (7.67%)	87 (13.18%)	5,116 (13.29%)
6 - <12 months	194 (9.17%)	357 (7.73%)	629 (7.04%)	557 (5.15%)	516 (4.54%)	35 (5.30%)	2,288 (5.94%)
1 - <2 years	214 (10.12%)	397 (8.59%)	699 (7.83%)	577 (5.34%)	607 (5.33%)	71 (10.76%)	2,565 (6.66%)
2 - 4 years	176 (8.32%)	389 (8.42%)	779 (8.72%)	498 (4.61%)	639 (5.62%)	52 (7.88%)	2,533 (6.58%)
5 - 17 years	41 (1.94%)	115 (2.49%)	267 (2.99%)	232 (2.15%)	256 (2.25%)	21 (3.18%)	932 (2.42%)
18 - 49 years	194 (9.17%)	412 (8.92%)	764 (8.56%)	960 (8.88%)	1,141 (10.03%)	71 (10.76%)	3,542 (9.20%)
50 - 64 years	245 (11.58%)	558 (12.08%)	1,014 (11.36%)	1,557 (14.41%)	1,708 (15.01%)	80 (12.12%)	5,162 (13.41%)
65 - 74 years	225 (10.64%)	567 (12.27%)	1,154 (12.92%)	1,797 (16.63%)	1,956 (17.19%)	84 (12.73%)	5,783 (15.02%)
75 - 84 years	169 (7.99%)	610 (13.20%)	1,202 (13.46%)	1,994 (18.45%)	2,189 (19.24%)	96 (14.55%)	6,260 (16.26%)
85+ years	106 (5.01%)	370 (8.01%)	833 (9.33%)	1,462 (13.53%)	1,493 (13.12%)	63 (9.55%)	4,327 (11.24%)
Sex							
Female	1,147 (54.23%)	2,389 (51.71%)	4,744 (53.13%)	5,905 (54.65%)	6,186 (54.37%)	365 (55.30%)	20,736 (53.85%)
Male	966 (45.67%)	2,222 (48.10%)	4,160 (46.59%)	4,864 (45.01%)	5,159 (45.34%)	291 (44.09%)	17,662 (45.87%)
Unknown	2 (0.09%)	9 (0.19%)	25 (0.28%)	37 (0.34%)	33 (0.29%)	4 (0.61%)	110 (0.29%)
Race							
White	1,386 (65.53%)	3,170 (68.61%)	5,898 (66.05%)	7,357 (68.08%)	7,265 (63.85%)	368 (55.76%)	25,444 (66.07%)
Black or African American	362 (17.12%)	542 (11.73%)	1,066 (11.94%)	1,312 (12.14%)	1,568 (13.78%)	126 (19.09%)	4,976 (12.92%)
Asian	35 (1.65%)	145 (3.14%)	319 (3.57%)	301 (2.79%)	347 (3.05%)	23 (3.48%)	1,170 (3.04%)
Native Hawaiian or Other Pacific Islander	17 (0.80%)	87 (1.88%)	171 (1.92%)	120 (1.11%)	184 (1.62%)	13 (1.97%)	592 (1.54%)
American Indian or Alaska Native	15 (0.71%)	49 (1.06%)	74 (0.83%)	67 (0.62%)	68 (0.60%)	4 (0.61%)	277 (0.72%)
Other Race	145 (6.86%)	236 (5.11%)	557 (6.24%)	543 (5.02%)	861 (7.57%)	78 (11.82%)	2,420 (6.28%)
Unknown	155 (7.33%)	391 (8.46%)	844 (9.45%)	1,106 (10.24%)	1,085 (9.54%)	48 (7.27%)	3,629 (9.42%)
Ethnicity							

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Unknown	153 (7.23%)	355 (7.68%)	682 (7.64%)	817 (7.56%)	822 (7.22%)	30 (4.55%)	2,859 (7.42%)
Hispanic or Latino	313 (14.80%)	639 (13.83%)	1,342 (15.03%)	1,369 (12.67%)	1,703 (14.97%)	147 (22.27%)	5,513 (14.32%)
Not Hispanic or Latino	1,649 (77.97%)	3,626 (78.48%)	6,905 (77.33%)	8,620 (79.77%)	8,853 (77.81%)	483 (73.18%)	30,136 (78.26%)
Unknown	153 (7.23%)	355 (7.68%)	682 (7.64%)	817 (7.56%)	822 (7.22%)	30 (4.55%)	2,859 (7.42%)
Comorbidity							
Asthma	252 (11.91%)	573 (12.40%)	1,181 (13.23%)	1,587 (14.69%)	1,845 (16.22%)	99 (15.00%)	5,537 (14.38%)
Chronic Lung Disease	136 (6.43%)	324 (7.01%)	627 (7.02%)	878 (8.13%)	1,086 (9.54%)	51 (7.73%)	3,102 (8.06%)
Chronic Obstructive Pulmonary Disease	300 (14.18%)	767 (16.60%)	1,487 (16.65%)	2,255 (20.87%)	2,367 (20.80%)	92 (13.94%)	7,268 (18.87%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2020

Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 8,388,324 RSV lab results with known results of which 382,190 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2020

Figure 23: Weekly RSV test positivity rate by season

Rhinovirus

Our rhinovirus study population consists of 102,977 hospitalizations of 69,889 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	6,345 (100.00%)	8,733 (100.00%)	14,307 (100.00%)	15,821 (100.00%)	20,313 (100.00%)	4,370 (100.00%)	69,889 (100.00%)
Age Group							
< 6 months	436 (6.87%)	712 (8.15%)	852 (5.96%)	825 (5.21%)	851 (4.19%)	140 (3.20%)	3,816 (5.46%)
6 - <12 months	263 (4.14%)	340 (3.89%)	433 (3.03%)	430 (2.72%)	465 (2.29%)	71 (1.62%)	2,002 (2.86%)
1 - <2 years	507 (7.99%)	657 (7.52%)	801 (5.60%)	742 (4.69%)	863 (4.25%)	141 (3.23%)	3,711 (5.31%)
2 - 4 years	466 (7.34%)	979 (11.21%)	1,181 (8.25%)	1,061 (6.71%)	1,175 (5.78%)	228 (5.22%)	5,090 (7.28%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
5 - 17 years	560 (8.83%)	940 (10.76%)	1,378 (9.63%)	1,512 (9.56%)	1,721 (8.47%)	316 (7.23%)	6,427 (9.20%)
18 - 49 years	1,377 (21.70%)	1,399 (16.02%)	2,470 (17.26%)	2,943 (18.60%)	3,929 (19.34%)	863 (19.75%)	12,981 (18.57%)
50 - 64 years	1,026 (16.17%)	1,231 (14.10%)	2,250 (15.73%)	2,475 (15.64%)	3,375 (16.61%)	833 (19.06%)	11,190 (16.01%)
65 - 74 years	781 (12.31%)	1,156 (13.24%)	2,190 (15.31%)	2,444 (15.45%)	3,287 (16.18%)	712 (16.29%)	10,570 (15.12%)
75 - 84 years	587 (9.25%)	821 (9.40%)	1,734 (12.12%)	2,076 (13.12%)	2,932 (14.43%)	679 (15.54%)	8,829 (12.63%)
85+ years	342 (5.39%)	498 (5.70%)	1,018 (7.12%)	1,313 (8.30%)	1,715 (8.44%)	387 (8.86%)	5,273 (7.54%)
Sex							
Female	3,246 (51.16%)	4,275 (48.95%)	7,179 (50.18%)	7,878 (49.79%)	10,146 (49.95%)	2,231 (51.05%)	34,955 (50.02%)
Male	3,086 (48.64%)	4,433 (50.76%)	7,084 (49.51%)	7,897 (49.91%)	10,102 (49.73%)	2,102 (48.10%)	34,704 (49.66%)
Other	0	0	0	0	1 (0.00%)	0	1 (0.00%)
Unknown	13 (0.20%)	25 (0.29%)	44 (0.31%)	46 (0.29%)	64 (0.32%)	37 (0.85%)	229 (0.33%)
Race							
White	4,101 (64.63%)	5,766 (66.03%)	9,135 (63.85%)	9,787 (61.86%)	12,670 (62.37%)	2,700 (61.78%)	44,159 (63.18%)
Black or African American	989 (15.59%)	1,300 (14.89%)	2,213 (15.47%)	2,461 (15.56%)	3,292 (16.21%)	769 (17.60%)	11,024 (15.77%)
Asian	144 (2.27%)	193 (2.21%)	345 (2.41%)	312 (1.97%)	409 (2.01%)	66 (1.51%)	1,469 (2.10%)
Native Hawaiian or Other Pacific Islander	63 (0.99%)	75 (0.86%)	80 (0.56%)	97 (0.61%)	127 (0.63%)	19 (0.43%)	461 (0.66%)
American Indian or Alaska Native	46 (0.72%)	80 (0.92%)	119 (0.83%)	101 (0.64%)	125 (0.62%)	27 (0.62%)	498 (0.71%)
Other Race	443 (6.98%)	633 (7.25%)	1,092 (7.63%)	1,498 (9.47%)	1,836 (9.04%)	381 (8.72%)	5,883 (8.42%)
Unknown	559 (8.81%)	686 (7.86%)	1,323 (9.25%)	1,565 (9.89%)	1,854 (9.13%)	408 (9.34%)	6,395 (9.15%)
Ethnicity							
Hispanic or Latino	755 (11.90%)	1,225 (14.03%)	2,232 (15.60%)	2,800 (17.70%)	3,477 (17.12%)	772 (17.67%)	11,261 (16.11%)
Not Hispanic or Latino	5,102 (80.41%)	6,910 (79.13%)	11,046 (77.21%)	11,917 (75.32%)	15,543 (76.52%)	3,393 (77.64%)	53,911 (77.14%)
Unknown	488 (7.69%)	598 (6.85%)	1,029 (7.19%)	1,104 (6.98%)	1,293 (6.37%)	205 (4.69%)	4,717 (6.75%)
Comorbidity							
Asthma	1,253 (19.75%)	1,557 (17.83%)	2,643 (18.47%)	2,959 (18.70%)	3,856 (18.98%)	843 (19.29%)	13,111 (18.76%)
Chronic Lung Disease	674 (10.62%)	778 (8.91%)	1,259 (8.80%)	1,321 (8.35%)	1,974 (9.72%)	406 (9.29%)	6,412 (9.17%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Chronic Obstructive Pulmonary Disease	1,211 (19.09%)	1,491 (17.07%)	2,563 (17.91%)	2,714 (17.15%)	3,791 (18.66%)	884 (20.23%)	12,654 (18.11%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 2,423,566 rhinovirus lab results with known results of which 403,518 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2020

Figure 27: Weekly rhinovirus test positivity rate by season

Infants and children (age 0-4)

Our infants and children study population consists of 71,822 hospitalizations of 47,922 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	5,008 (100.00%)	9,609 (100.00%)	12,640 (100.00%)	10,059 (100.00%)	9,401 (100.00%)	1,205 (100.00%)	47,922 (100.00%)
Age Group							
< 6 months	1,683 (33.61%)	3,017 (31.40%)	3,998 (31.63%)	3,188 (31.69%)	2,487 (26.45%)	301 (24.98%)	14,674 (30.62%)
6 - <12 months	746 (14.90%)	1,446 (15.05%)	1,987 (15.72%)	1,733 (17.23%)	1,516 (16.13%)	157 (13.03%)	7,585 (15.83%)
1 - <2 years	1,238 (24.72%)	2,069 (21.53%)	2,716 (21.49%)	2,263 (22.50%)	2,366 (25.17%)	321 (26.64%)	10,973 (22.90%)
2 - 4 years	1,341 (26.78%)	3,077 (32.02%)	3,939 (31.16%)	2,875 (28.58%)	3,032 (32.25%)	426 (35.35%)	14,690 (30.65%)
Sex							
Female	2,134 (42.61%)	4,027 (41.91%)	5,446 (43.09%)	4,350 (43.24%)	4,070 (43.29%)	500 (41.49%)	20,527 (42.83%)
Male	2,874 (57.39%)	5,580 (58.07%)	7,193 (56.91%)	5,706 (56.73%)	5,329 (56.69%)	705 (58.51%)	27,387 (57.15%)
Unknown	0	2 (0.02%)	1 (0.01%)	3 (0.03%)	2 (0.02%)	0	8 (0.02%)
Race							

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
White	2,572 (51.36%)	5,012 (52.16%)	6,247 (49.42%)	4,939 (49.10%)	4,600 (48.93%)	602 (49.96%)	23,972 (50.02%)
Black or African American	884 (17.65%)	1,499 (15.60%)	1,957 (15.48%)	1,577 (15.68%)	1,518 (16.15%)	223 (18.51%)	7,658 (15.98%)
Asian	225 (4.49%)	572 (5.95%)	889 (7.03%)	555 (5.52%)	455 (4.84%)	41 (3.40%)	2,737 (5.71%)
Native Hawaiian or Other Pacific Islander	88 (1.76%)	202 (2.10%)	254 (2.01%)	241 (2.40%)	259 (2.76%)	22 (1.83%)	1,066 (2.22%)
American Indian or Alaska Native	43 (0.86%)	111 (1.16%)	164 (1.30%)	82 (0.82%)	73 (0.78%)	10 (0.83%)	483 (1.01%)
Other Race	882 (17.61%)	1,464 (15.24%)	1,961 (15.51%)	1,572 (15.63%)	1,575 (16.75%)	216 (17.93%)	7,670 (16.01%)
Unknown	314 (6.27%)	749 (7.79%)	1,168 (9.24%)	1,093 (10.87%)	921 (9.80%)	91 (7.55%)	4,336 (9.05%)
Ethnicity							
Hispanic or Latino	1,089 (21.75%)	2,125 (22.11%)	3,202 (25.33%)	2,681 (26.65%)	2,681 (28.52%)	342 (28.38%)	12,120 (25.29%)
Not Hispanic or Latino	3,586 (71.61%)	6,855 (71.34%)	8,603 (68.06%)	6,822 (67.82%)	6,139 (65.30%)	811 (67.30%)	32,816 (68.48%)
Unknown	333 (6.65%)	629 (6.55%)	835 (6.61%)	556 (5.53%)	581 (6.18%)	52 (4.32%)	2,986 (6.23%)
Virus							
COVID	592 (11.82%)	1,655 (17.22%)	831 (6.57%)	1,144 (11.37%)	1,708 (18.17%)	192 (15.93%)	6,122 (12.77%)
HMPV	25 (0.50%)	588 (6.12%)	842 (6.66%)	485 (4.82%)	533 (5.67%)	21 (1.74%)	2,494 (5.20%)
RSV	1,135 (22.66%)	1,988 (20.69%)	3,695 (29.23%)	2,804 (27.88%)	2,635 (28.03%)	245 (20.33%)	12,502 (26.09%)
influenza	1,248 (24.92%)	2,274 (23.67%)	3,262 (25.81%)	1,993 (19.81%)	647 (6.88%)	42 (3.49%)	9,466 (19.75%)
parainfluenza	336 (6.71%)	416 (4.33%)	743 (5.88%)	575 (5.72%)	524 (5.57%)	125 (10.37%)	2,719 (5.67%)
rhinovirus	1,672 (33.39%)	2,688 (27.97%)	3,267 (25.85%)	3,058 (30.40%)	3,354 (35.68%)	580 (48.13%)	14,619 (30.51%)
Comorbidity							
Asthma	378 (7.55%)	596 (6.20%)	853 (6.75%)	786 (7.81%)	919 (9.78%)	118 (9.79%)	3,650 (7.62%)
Chronic Lung Disease	33 (0.66%)	55 (0.57%)	82 (0.65%)	71 (0.71%)	72 (0.77%)	15 (1.24%)	328 (0.68%)
Chronic Obstructive Pulmonary Disease	9 (0.18%)	16 (0.17%)	19 (0.15%)	20 (0.20%)	13 (0.14%)	3 (0.25%)	80 (0.17%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Test positivity rate over time

We included 7,765,165 lab results with known results of infants and children under age five. Of those tests, 924,659 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2020 for infants and children under five

Older adults (age 65 and over)

Our older adults study population consists of 486,784 hospitalizations of 434,057 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	89,767 (100.00%)	103,808 (100.00%)	85,039 (100.00%)	83,552 (100.00%)	67,112 (100.00%)	4,779 (100.00%)	434,057 (100.00%)
Age Group							
65 - 74 years	38,862 (43.29%)	40,631 (39.14%)	28,811 (33.88%)	28,394 (33.98%)	23,754 (35.39%)	1,731 (36.22%)	162,183 (37.36%)
75 - 84 years	32,504 (36.21%)	38,679 (37.26%)	32,987 (38.79%)	32,898 (39.37%)	26,467 (39.44%)	1,864 (39.00%)	165,399 (38.11%)
85+ years	18,401 (20.50%)	24,498 (23.60%)	23,241 (27.33%)	22,260 (26.64%)	16,891 (25.17%)	1,184 (24.78%)	106,475 (24.53%)
Sex							
Female	44,281 (49.33%)	52,323 (50.40%)	44,934 (52.84%)	43,953 (52.61%)	36,152 (53.87%)	2,486 (52.02%)	224,129 (51.64%)
Male	45,128 (50.27%)	51,074 (49.20%)	39,730 (46.72%)	39,185 (46.90%)	30,687 (45.73%)	2,229 (46.64%)	208,033 (47.93%)
Unknown	358 (0.40%)	411 (0.40%)	375 (0.44%)	414 (0.50%)	273 (0.41%)	64 (1.34%)	1,895 (0.44%)
Race							
White	65,098 (72.52%)	77,905 (75.05%)	63,459 (74.62%)	61,001 (73.01%)	49,516 (73.78%)	3,444 (72.07%)	320,423 (73.82%)
Black or African American	9,788 (10.90%)	10,644 (10.25%)	8,353 (9.82%)	8,998 (10.77%)	6,751 (10.06%)	490 (10.25%)	45,024 (10.37%)
Asian	1,612 (1.80%)	1,806 (1.74%)	1,919 (2.26%)	1,991 (2.38%)	1,748 (2.60%)	131 (2.74%)	9,207 (2.12%)
Native Hawaiian or Other Pacific Islander	152 (0.17%)	184 (0.18%)	163 (0.19%)	158 (0.19%)	149 (0.22%)	13 (0.27%)	819 (0.19%)
American Indian or Alaska Native	244 (0.27%)	318 (0.31%)	314 (0.37%)	294 (0.35%)	259 (0.39%)	16 (0.33%)	1,445 (0.33%)
Other Race	3,153 (3.51%)	2,948 (2.84%)	2,909 (3.42%)	3,210 (3.84%)	3,015 (4.49%)	258 (5.40%)	15,493 (3.57%)
Unknown	9,720 (10.83%)	10,003 (9.64%)	7,922 (9.32%)	7,900 (9.46%)	5,674 (8.45%)	427 (8.93%)	41,646 (9.59%)
Ethnicity							
Hispanic or Latino	4,616 (5.14%)	4,104 (3.95%)	4,083 (4.80%)	4,863 (5.82%)	4,692 (6.99%)	408 (8.54%)	22,766 (5.24%)
Not Hispanic or Latino	74,234 (82.70%)	89,265 (85.99%)	72,954 (85.79%)	71,141 (85.15%)	57,458 (85.62%)	4,094 (85.67%)	369,146 (85.05%)
Unknown	10,917 (12.16%)	10,439 (10.06%)	8,002 (9.41%)	7,548 (9.03%)	4,962 (7.39%)	277 (5.80%)	42,145 (9.71%)
Virus							
COVID	84,347 (93.96%)	92,085 (88.71%)	56,715 (66.69%)	50,321 (60.23%)	23,923 (35.65%)	1,710 (35.78%)	309,101 (71.21%)
HMPV	26 (0.03%)	1,189 (1.15%)	2,321 (2.73%)	2,058 (2.46%)	2,825 (4.21%)	97 (2.03%)	8,516 (1.96%)
RSV	500 (0.56%)	1,547 (1.49%)	3,189 (3.75%)	5,253 (6.29%)	5,638 (8.40%)	243 (5.08%)	16,370 (3.77%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
influenza	2,672 (2.98%)	5,530 (5.33%)	15,817 (18.60%)	17,685 (21.17%)	24,013 (35.78%)	658 (13.77%)	66,375 (15.29%)
parainfluenza	512 (0.57%)	982 (0.95%)	2,055 (2.42%)	2,402 (2.87%)	2,779 (4.14%)	293 (6.13%)	9,023 (2.08%)
rhinovirus	1,710 (1.90%)	2,475 (2.38%)	4,942 (5.81%)	5,833 (6.98%)	7,934 (11.82%)	1,778 (37.20%)	24,672 (5.68%)
Comorbidity							
Asthma	7,198 (8.02%)	9,493 (9.14%)	9,175 (10.79%)	9,689 (11.60%)	8,927 (13.30%)	647 (13.54%)	45,129 (10.40%)
Chronic Lung Disease	6,589 (7.34%)	8,163 (7.86%)	7,568 (8.90%)	7,659 (9.17%)	7,452 (11.10%)	554 (11.59%)	37,985 (8.75%)
Chronic Obstructive Pulmonary Disease	15,966 (17.79%)	22,665 (21.83%)	20,227 (23.79%)	21,259 (25.44%)	18,443 (27.48%)	1,294 (27.08%)	99,854 (23.00%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Test positivity rate over time

We included 19,991,029 lab results with known results of adults aged 65 and over. Of those tests, 1,361,669 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2020 for adults 65 years or older

Discussion and conclusion

In the last week of November, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations, an increase from 1.3% at the beginning of the month (+91.1%). Influenza-associated hospitalizations increased from 0.2% of to 0.8% of all hospitalizations (+264.7%), COIVD-associated hospitalizations increased from 0.3% to 0.5% of all hospitalizations (+40.2%), RSV increased slightly from 0.1% to 0.3% of all hospitalizations, and rhinovirus-associated hospitalizations increased slightly from 0.8% to 1.0% of all hospitalizations. HMPV-, parainfluenza-associated hospitalizations all remained relatively low and stable across the month.

Influenza, HMPV, and RSV test positivity increased notably (+172.6%, +134.4%, and +94.9%, respectively), while parainfluenza and COVID test positivity increased slightly (+15.4% and +6.4%, respectively). Rhinovirus continued to show the highest positivity levels (17.6%) but decreased this month. These data suggest that although respiratory virus associated hospitalizations remained low overall in November, hospitalizations associated with respiratory viruses are beginning to increase. Increases were observed across most respiratory viruses in both hospitalizations and test positivity. Rhinovirus continued to account for the largest share of virus-associated hospitalizations and maintained the highest positivity levels, while notable increases in influenza-associated hospitalizations were also observed.

In the population aged 0–4 years, respiratory virus–associated hospitalizations increased substantially throughout November and are now at a rate of 3.9% of all hospitalizations in this age group (+73.1%). For the third month in a row, the rate of

RSV-associated hospitalizations more than doubled, now accounting for 1.5% of all hospitalizations within this age group. Parainfluenza- and influenza- associated hospitalizations also increased substantially across this month (155.1% and +62.3%, respectively), while COVID- and rhinovirus increased modestly (+33.6% and 28.1%, respectively). Rhinovirus (1.8%) continues to account for the largest share of respiratory virus associated hospitalizations in this age group, although RSV (1.5%) is now a close second.

In this pediatric population, HMPV, influenza, RSV, and test positivity increased substantially (+202.8%, +157.1%, +71.5%, respectively). COVID test positivity increased slightly (+16.4 percent), while rhinovirus and parainfluenza test positivity declined. Rhinovirus remained the virus with the highest test positivity rate (38.0 %) despite this decrease. These data demonstrate that respiratory virus-associated hospitalizations are increasing among children aged 0 to 4 years, marked by increasing RSV- and influenza-associated hospitalizations.

Among adults aged 65 years and older, respiratory virus–associated hospitalizations accounted for 2.8% of all hospitalizations in the last week of November 2025, an increase from 1.3% at the beginning of the month (+115.9%). Influenza-associated hospitalizations increased substantially (+374.1 percent) and now represent 0.9 % of all hospitalizations in this age group. COVID-associated hospitalizations increased modestly, from 0.4% to 0.6% (+37.7%). Rhinovirus associated hospitalizations also increased modestly, from 0.6% to 0.9% (+61.0%). RSV, parainfluenza, and HMPV associated hospitalizations remained low and relatively stable across the month.

In this older adult population, influenza test positivity increased sharply (+164.9 percent). Parainfluenza, RSV, and HMPV positivity also increased across the month (+116.0%, +106.6%, and +96.3%, respectively). COVID test positivity remained stable, while rhinovirus positivity increased slightly (+13.1 percent) and continued to be the highest among all respiratory viruses.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed December 10, 2025. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic

health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., … Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza

Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., … Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy